This MedLibrary.org supplementary page on Atracurium is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Atracurium
|
|
| Systematic (IUPAC) name | |
| 2,2'-{1,5-Pentanediylbis[oxy(3-oxo-3,1-
propanediyl)]}bis[1-(3,4-dimethoxybenzyl) -6,7-dimethoxy-2-methyl-1,2,3,4- tetrahydroisoquinolinium] |
|
| Identifiers | |
| CAS number | |
| ATC code | M03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C53H72N2O122+ |
| Mol. mass | 929.145 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 100% (IV) |
| Protein binding | 82% |
| Metabolism | Hofmann elimination (retro-Michael addition) and ester hydrolysis |
| Half life | 17-21 minutes |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
POM (UK)and worldwide |
| Routes | IV |
Atracurium is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Side effects owing to histamine liberation are rash, reflex increase in heart rate, low blood pressure and bronchospasm.
It is a bisbenzyltetrahydroisoquinolinium mixture of 10 stereoisomers. Atracurium was first synthesized, in 1974 by George H. Dewar, in John B. Stenlake's medicinal chemistry research group at Strathclyde University, Scotland. It is the first non-depolarising non-steroidal skeletal muscle relaxant rationally designed to undergo chemodegradation in vivo. Atracurium was licensed to Burroughs Wellcome Co., which developed atracurium and eventually marketed it (as a mixture of all ten stereoisomers) under the name Tracrium. Atracurium's rate of degradation in vivo is influenced by pH and temperature.
Atracurium was succeeded by cisatracurium, which is the R-cis R-cis isomer constituent of atracurium. The pharmacodynamic and adverse effects profile of cisatracurium proved to be superior to that of atracurium. Cisatracurium was made available worldwide as Nimbex in 1995, with its clinical development solely undertaken by Burroughs Wellcome Co.
Atracurium is classified as an intermediate-acting non-depolarising neuromuscular blocking agent.
|
|||||||||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 18 September 2008, at 22:00.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Atracurium".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.